NCT00426751 - Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI) | Biotech Hunter

Enrollment

429

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Infarction, Myocardial

Interventions

DRUG

Abciximab

Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.

DRUG

Eptifibatide

Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.

Trial Locations (24)

14033

GSK Investigational Site, Caen

33076

GSK Investigational Site, Bordeaux

33604

GSK Investigational Site, Pessac

41063

GSK Investigational Site, Mönchengladbach

41464

GSK Investigational Site, Neuss

44137

GSK Investigational Site, Dortmund

52074

GSK Investigational Site, Aachen

54000

GSK Investigational Site, Nancy

54511

GSK Investigational Site, Vandœuvre-lès-Nancy

59037

GSK Investigational Site, Lille

61014

GSK Investigational Site, Alençon

63069

GSK Investigational Site, Offenbach

64046

GSK Investigational Site, Pau

66000

GSK Investigational Site, Perpignan

66421

GSK Investigational Site, Homburg

67063

GSK Investigational Site, Ludwigshafen am Rhein

69120

GSK Investigational Site, Heidelberg

77000

GSK Investigational Site, Melun

77007

GSK Investigational Site, Melun

79106

GSK Investigational Site, Freiburg im Breisgau

83056

GSK Investigational Site, Toulon

83190

GSK Investigational Site, Ollioules

94010

GSK Investigational Site, Créteil

97080

GSK Investigational Site, Würzburg